5AM Ventures
Life sciences VC with consistent infectious-disease exposure across therapeutics and diagnostics. Life sciences VC with consistent infectious-disease exposure across therapeutics and diagnostics.
Resource Directory
Connecting the right capital with the right projects
Addressing AMR requires sustained investment across the comprehensive research and development continuum, from early discovery through clinical development, commercialization, and global access. This directory maps venture capital, private equity, public agencies, philanthropic organizations, and public-private partnerships that direct capital toward the AMR response, making it easier to identify funding sources and build partnerships.
Seeking funding for your AMR project or program? Complete our Seeking Resources form, tell us about your project, and we will see if we can help.
Tell Us About Your AMR ProjectLife sciences VC with consistent infectious-disease exposure across therapeutics and diagnostics. Life sciences VC with consistent infectious-disease exposure across therapeutics and diagnostics.
Longstanding life sciences investor known for backing development-stage therapeutics and commercial growth stories. Longstanding life sciences investor known for backing development-stage therapeutics and commercial growth stories.
Early-stage life-science venture and company-building firm that works closely with academic and translational founders. Early-stage life-science venture and company-building firm that works closely with academic and translational founders.
European venture investor focused on innovative life science companies across therapeutics and enabling technologies. European venture investor focused on innovative life science companies across therapeutics and enabling technologies.
The AMR Action Fund is a large-scale investment initiative backed by major pharmaceutical companies to support the late-stage development of new antibiotics and bring them to market. The AMR Action Fund is a large-scale investment initiative backed by major pharmaceutical companies to support the late-stage development of new antibiotics and bring them to market.
UN multi-partner pooled fund supporting implementation of national AMR action plans and One Health coordination with sustainable financing structures. UN multi-partner pooled fund supporting implementation of national AMR action plans and One Health coordination with sustainable financing structures.
Major science-first venture firm with a strong company-creation model across breakthrough biology. Major science-first venture firm with a strong company-creation model across breakthrough biology.
Frontier-tech and health investor with a documented lead investment in Locus Biosciences, a precision antimicrobial company. Frontier-tech and health investor with a documented lead investment in Locus Biosciences, a precision antimicrobial company.
Company-creation biotech VC with deep scientific involvement at formation stage. Company-creation biotech VC with deep scientific involvement at formation stage.
US government medical countermeasure funder with a dedicated antibacterial countermeasures program supporting therapeutics and diagnostics against resistant pathogens. US government medical countermeasure funder with a dedicated antibacterial countermeasures program supporting therapeutics and diagnostics against resistant pathogens.
Global health philanthropy that funds AMR-relevant diagnostics, surveillance, access, and selective therapeutic innovation, especially where global health burden is high. Global health philanthropy that funds AMR-relevant diagnostics, surveillance, access, and selective therapeutic innovation, especially where global health burden is high.
Danish life-science incubator and funding platform that provides early-stage capital, venture building, and infrastructure to startups, including infectious-disease and diagnostics projects. Danish life-science incubator and funding platform that provides early-stage capital, venture building, and infrastructure to startups, including infectious-disease and diagnostics projects.
UK research council supporting biological science, microbiology, engineering biology, and One Health work that can underpin AMR innovation. UK research council supporting biological science, microbiology, engineering biology, and One Health work that can underpin AMR innovation.
Corporate venture fund of Boehringer Ingelheim that explicitly includes anti-infectives / AMR as a portfolio area. Corporate venture fund of Boehringer Ingelheim that explicitly includes anti-infectives / AMR as a portfolio area.
CARB-X is a global non-profit partnership focused exclusively on accelerating the development of new antibiotics, diagnostics, vaccines, and other products to combat antimicrobial resistance. It is funded by a coalition of governments and foundations. CARB-X is a global non-profit partnership focused exclusively on accelerating the development of new antibiotics, diagnostics, vaccines, and other products to combat antimicrobial resistance. It is funded by a coalition of governments and foundations.
CDC funds surveillance, laboratories, and selected innovative research projects to respond to antimicrobial resistance across the public-health system. CDC funds surveillance, laboratories, and selected innovative research projects to respond to antimicrobial resistance across the public-health system.
Venture-philanthropy arm of the Cystic Fibrosis Foundation, relevant because CF care depends heavily on anti-infective innovation including resistant respiratory pathogens and alternative modalities. Venture-philanthropy arm of the Cystic Fibrosis Foundation, relevant because CF care depends heavily on anti-infective innovation including resistant respiratory pathogens and alternative modalities.
Healthcare investment platform with flexible financing, venture creation, and translational support across therapeutics, diagnostics, and health systems. Healthcare investment platform with flexible financing, venture creation, and translational support across therapeutics, diagnostics, and health systems.
Formerly LSP, one of Europe's most experienced life-science investors across therapeutics, diagnostics, and healthtech. Formerly LSP, one of Europe's most experienced life-science investors across therapeutics, diagnostics, and healthtech.
EU innovation vehicle offering grants and blended finance to deep-tech and life science companies, including diagnostics and therapeutic platforms relevant to AMR. EU innovation vehicle offering grants and blended finance to deep-tech and life science companies, including diagnostics and therapeutic platforms relevant to AMR.
Stay connected so that you don't miss the latest AMR insights and updates.